31 research outputs found

    Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration

    Get PDF
    During the last years the potential role of in vitro transcribed (IVT) mRNA as a vehicle to deliver genetic information has come into focus. IVT mRNA could be used for anti-cancer therapies, vaccination purposes, generation of pluripotent stem cells and also for genome engineering or protein replacement. However, the administration of IVT mRNA into the target organ is still challenging. The lung with its large surface area is not only of interest for delivery of genetic information for treatment of e.g. for cystic fibrosis or alpha-1-antitrypsin deficiency, but also for vaccination purposes. Administration of IVT mRNA to the lung can be performed by direct intratracheal instillation or by aerosol inhalation/nebulisation. The latter approach shows a non-invasive tool, although it is not known, if IVT mRNA is resistant during the process of nebulisation. Therefore, we investigated the transfection efficiency of non-nebulised and nebulised IVT mRNA polyplexes and lipoplexes in human bronchial epithelial cells (16HBE). A slight reduction in transfection efficiency was observed for lipoplexes (Lipofectamine 2000) in the nebulised part compared to the non-nebulised which can be overcome by increasing the amount of Lipofectamine. However, Lipofectamine was more than three times more efficient in transfecting 16HBE than DMRIE and linear PEI performed almost 10 times better than its branched derivative. By contrast, the nebulisation process did not affect the cationic polymer complexes. Furthermore, aerosolisation of IVT mRNA complexes did neither affect the protein duration nor the toxicity of the cationic complexes. Taken together, these data show that aerosolisation of cationic IVT mRNA complexes constitute a potentially powerful means to transfect cells in the lung with the purpose of protein replacement for genetic diseases such as cystic fibrosis or alpha-1-antitrypsin deficiency or for infectious disease vaccines, while bringing along the advantages of IVT mRNA as compared to pDNA as transfection agent

    Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration

    Get PDF
    During the last years the potential role of in vitro transcribed (IVT) mRNA as a vehicle to deliver genetic information has come into focus. IVT mRNA could be used for anti-cancer therapies, vaccination purposes, generation of pluripotent stem cells and also for genome engineering or protein replacement. However, the administration of IVT mRNA into the target organ is still challenging. The lung with its large surface area is not only of interest for delivery of genetic information for treatment of e.g. for cystic fibrosis or alpha-1-antitrypsin deficiency, but also for vaccination purposes. Administration of IVT mRNA to the lung can be performed by direct intratracheal instillation or by aerosol inhalation/nebulisation. The latter approach shows a non-invasive tool, although it is not known, if IVT mRNA is resistant during the process of nebulisation. Therefore, we investigated the transfection efficiency of non-nebulised and nebulised IVT mRNA polyplexes and lipoplexes in human bronchial epithelial cells (16HBE). A slight reduction in transfection efficiency was observed for lipoplexes (Lipofectamine 2000) in the nebulised part compared to the non-nebulised which can be overcome by increasing the amount of Lipofectamine. However, Lipofectamine was more than three times more efficient in transfecting 16HBE than DMRIE and linear PEI performed almost 10 times better than its branched derivative. By contrast, the nebulisation process did not affect the cationic polymer complexes. Furthermore, aerosolisation of IVT mRNA complexes did neither affect the protein duration nor the toxicity of the cationic complexes. Taken together, these data show that aerosolisation of cationic IVT mRNA complexes constitute a potentially powerful means to transfect cells in the lung with the purpose of protein replacement for genetic diseases such as cystic fibrosis or alpha-1-antitrypsin deficiency or for infectious disease vaccines, while bringing along the advantages of IVT mRNA as compared to pDNA as transfection agent

    Transcription-dependent spatial arrangements of CFTR and adjacent genes in human cell nuclei

    Get PDF
    We investigated in different human cell types nuclear positioning and transcriptional regulation of the functionally unrelated genes GASZ, CFTR, and CORTBP2, mapping to adjacent loci on human chromosome 7q31. When inactive, GASZ, CFTR, and CORTBP2 preferentially associated with the nuclear periphery and with perinuclear heterochromatin, whereas in their actively transcribed states the gene loci preferentially associated with euchromatin in the nuclear interior. Adjacent genes associated simultaneously with these distinct chromatin fractions localizing at different nuclear regions, in accordance with their individual transcriptional regulation. Although the nuclear localization of CFTR changed after altering its transcription levels, the transcriptional status of CFTR was not changed by driving this gene into a different nuclear environment. This implied that the transcriptional activity affected the nuclear positioning, and not vice versa. Together, the results show that small chromosomal subregions can display highly flexible nuclear organizations that are regulated at the level of individual genes in a transcription-dependent manner

    Characterization of Ku702–NLS as Bipartite Nuclear Localization Sequence for Non-Viral Gene Delivery

    Get PDF
    Several barriers have to be overcome in order to achieve gene expression in target cells, e.g. cellular uptake, endosomal release and translocation to the nucleus. Nuclear localization sequences (NLS) enhance gene delivery by increasing the uptake of plasmid DNA (pDNA) to the nucleus. So far, only monopartite NLS were analysed for non-viral gene delivery. In this study, we examined the characteristics of a novel bipartite NLS like construct, namely NLS Ku70. We synthesized a dimeric structure of a modified NLS from the Ku70 protein (Ku702-NLS), a nuclear transport active mutant of Ku702-NLS (s1Ku702-NLS) and a nuclear transport deficient mutant of Ku702-NLS (s2Ku702). We examined the transfection efficiency of binary Ku702-NLS/DNA and ternary Ku702-NLS/PEI/DNA gene vector complexes in vitro by using standard transfection protocols as well as the magnetofection method. The application of Ku702-NLS and s1Ku702-NLS increased gene transfer efficiency in vitro and in vivo. This study shows for the first time that the use of bipartite NLS compounds alone or in combination with cationic polymers is a promising strategy to enhance the efficiency of non-viral gene transfer

    Gene and cell therapy for cystic fibrosis: From bench to bedside

    Get PDF
    Clinical trials in cystic fibrosis (CF) patients established proof-of-principle for transfer of the wild-type cystic fibrosis transmembrane conductance regulator (CFTR) gene to airway epithelial cells. However, the limited efficacy of gene transfer vectors as well as extra- and intracellular barriers have prevented the development of a gene therapy-based treatment for CF. Here, we review the use of new viral and nonviral gene therapy vectors, as well as human artificial chromosomes, to overcome barriers to successful CFTR expression. Pre-clinical studies will surely benefit from novel animal models, such as CF pigs and ferrets. Prenatal gene therapy is a potential alternative to gene transfer to fully developed lungs. However, unresolved issues, including the possibility of adverse effects on pre- and postnatal development, the risk of initiating oncogenic or degenerative processes and germ line transmission require further investigation. Finally, we discuss the therapeutic potential of stem cells for CF lung disease. (C) 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved

    World Congress Integrative Medicine & Health 2017: Part one

    Get PDF

    Transfection efficiency in human bronchial epithelia cells (16HBE)–luciferase activity.

    No full text
    <p>Lipo- and polyplexes were prepared as described in the material and methods section. A fraction of the complexes was kept apart and used as a non-nebulised control (white bars). The rest of the solution was aerosolized for 5 minutes by employing a PARI Boy® Nebulizer (black bars) and collected. Nebulised and non-nebulised complexes were incubated with 16HBE cells for 2 h. Luciferase activity in 50 μl of supernatants was assayed after 24 h and its activity is expressed in relative light units, n ≥ 6. The average relative light units have been employed to evaluate differences between samples. 100 ng of mRNA complexed with 1.2 μl of Lipofectamine or 1.5 μl DMRIE or 0.8 μl linPEI or 0.9 μl brPEI (500 ng) were added per well; **p < 0.001.</p

    Effect of different solutions on the transfection efficiency of lipoplexes.

    No full text
    <p>Lipoplexes were prepared in OpiMem but diluted in sodium chloride solution (0.9%). A fraction of the complexes was kept apart and used as a non-nebulised control. The rest of the solution was aerosolized for 5 minutes by employing a PARI Boy® Nebulizer and collected. 100 ng of IVT mRNA encoding Metridia luciferase were complexed with 1.2 μl of Lipofectamine and subsequently added per well. Nebulised and non-nebulised complexes were incubated with 16HBE cells for 2 h. Luciferase activity in 50 μl of supernatants was assayed every 24 h till the relative light units measured with a luminometer dropped below 100. The media on the cells were replaced daily after collecting samples for analysis. Enzyme activity is expressed in relative light units. n = 5; *p < 0.01.</p

    Transfection efficiency in human bronchial epithelia cells—the effect of the charge ratio at which mRNA and cationic lipids are mixed.

    No full text
    <p>Lipoplexes were prepared in OptiMem. A fraction of the complexes was kept apart and used as a non-nebulised control. The rest of the solution was aerosolized for 5 minutes by employing a PARI Boy® Nebulizer and collected. 100 ng of mRNA encoding Metridia luciferase were complexed with Lipofectamine (condition 1–1.2 μl; condition 2–1.8 μl) (A) or DMRIE (condition 1–1.2 μl; condition 2–1.5 μl; condition 3–1.8 μl) (B) were added per well. Nebulised and non-nebulized complexes were incubated with 16HBE cells for 2 h. Luciferase activity in 50 μl of supernatants was assayed with a luminometer. The enzyme activity is expressed in relative light units, n = 5. *p < 0.01; **p < 0.001.</p
    corecore